AI assistant
TherapeuticsMD, Inc. — Director's Dealing 2014
Jun 9, 2014
35134_dirs_2014-06-09_259bb5fb-67e1-4845-b6e9-38eaa4334c76.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2014-06-05
Reporting Person: Bernick Brian (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-06-05 | Common Stock | M | 10000 | $0.1018 | Acquired | 6745999 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-06-05 | Stock Option (right to buy) | $0.1018 | M | 10000 | Disposed | 2019-01-01 | Common Stock (10000) | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 297000 | Direct |
| Common Stock | 3000 | Indirect |
Footnotes
F1: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The reporting person (i) holds, together with his spouse as tenants by the entirety, 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The reporting person disclaims beneficial ownership of TherapeuticsMD, Inc. (the "Company") common stock except to the extent of his pecuniary interest therein.
F2: The reported securities are held by the GP. As disclosed in footnote 1 above, the reporting person, together with his spouse as tenants by the entirety, hold 70.6% membership interest in the GP. The reporting person disclaims beneficial ownership of the Company common stock except to the extent of his pecuniary interest therein.
F3: The stock option vested at the rate of 40,914 shares per month over three years from February 1, 2009. This stock option was assumed and re-issued pursuant to the Agreement and Plan of Merger among the Company, VitaMedMD, LLC, and VitaMed Acquisition, LLC, dated as of October 4, 2011. The stock option, as assumed, retained the vesting schedule of the original stock option.